Coley's Lessons Remembered: Augmenting Mistletoe Therapy

Integrative Cancer Therapies

Volumn 15, Issue 4, 2016, Pages 502-511

  Orange, Maurice ^a   Reuter, Uwe ^b   Hobohm, Uwe ^c  

^a Klinik Arlesheim   (Switzerland)

^b Klinik im LEBEN   (Germany)

^c TECHNISCHE HOCHSCHULE MITTELHESSEN   (Germany)

Author keywords

cancer immunotherapy; Coley's toxin; mistletoe lectin; mistletoe therapy; pattern recognition receptor ligand; spontaneous regression

Indexed keywords

BACTERIAL EXTRACT; LIGAND; PATTERN RECOGNITION RECEPTOR; PATTERN RECOGNITION RECEPTOR LIGAND; UNCLASSIFIED DRUG; VISCUM ALBUM LECTIN; BIOLOGICAL PRODUCT;

AUGMENTED MISTLETOE THERAPY; CANCER IMMUNOLOGY; CANCER THERAPY; DRUG APPROVAL; EPIDEMIOLOGICAL DATA; EXPERIMENTAL THERAPY; FEASIBILITY STUDY; HUMAN; IMMUNOGENICITY; INFECTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; SOLID TUMOR; ANIMAL; BACTERIUM; IMMUNOLOGY; MICROBIOLOGY; NEOPLASM;

ANIMALS; BACTERIA; BIOLOGICAL PRODUCTS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION;

EID: 84995745487     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735416649916     Document Type: Review

References (60)

1. Busch W., Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr. 1868; 5: 137.
2. Fehleisen F., Über die Züchtung der Erysipelkokken auf künstlichem Nährboden und ihre Übertragbarkeit auf den Menschen. Dtsch Med Wochenschr. 1882; 85: 553-554.
3. Coley-Nauts HC, Fowler GAA, Bogatko FH., A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand. 1953; 145: 5-102.
4. Nauts HC, McLaren JR., Coley toxins: the first century. Adv Exp Med Biol. 1990; 267: 483-500.
5. Hall S., A Commotion in the Blood. Brighton, Australia: Owl Publishing; 1998.
6. Christian S, Palmer L., An apparent recovery from multiple sarcoma with involvement of both bone and soft parts treated by toxin of erysipelas and bacillus prodigiosus. Am J Surg. 1928; 43: 188-197.
7. Wiemann B, Starnes CO., Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994; 64: 529-564.
8. Klyuyeva NG, Roskin GI., Biotherapy of Malignant Tumours. Oxford, UK: Pergamon Press; 1963.
9. Hobohm U., Fever and cancer in perspective. Cancer Immunol Immunother. 2001; 50: 391-396.
10. Stephenson HE Jr, Delmez JA, Renden DI, et al. Host immunity and spontaneous regression of cancer evaluated by computerized data reduction study. Surg Gynecol Obstet. 1971; 133: 649-655.
11. Diamond LK, Luhby LA., Pattern of "spontaneous" remissions in leukemia of the childhood, observed in 26 of 300 cases. Am J Med. 1951; 10: 238ff.
12. Mantovani A, Pierotti MA., Cancer and inflammation: a complex relationship. Cancer Lett. 2008; 267: 180-181.
13. Maletzki C, Linnebacher M, Savai R, Hobohm U., Mistletoe lectin has a shiga toxin-like structure and should be combined with other toll-like receptor ligands in cancer therapy. Cancer Immunol Immunother. 2013; 62: 1283-1292.
14. Hobohm U, Stanford JL, Grange JM., Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol. 2008; 28: 95-107.
15. Oth T, Van Elssen CH, Schnijderberg MC, et al. Potency of both human Th1 and NK helper cell activation is determined by IL-12p70-producing PAMP-matured DCs. J Interferon Cytokine Res. 2015; 35: 748-758.
16. Kaczanowska S, Joseph AM, Davila E., TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013; 93: 847-863.
17. Ruprecht CR, Lanzavecchia A., Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006; 36: 810-816.
18. Palm NW, Medzhitov R., Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009; 227: 221-233.
19. Wherry EJ, Kurachi M., Molecular and cellular insights into T cell exhaustion. Nat Rev. 2015; 15: 486-499.
20. Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF., Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006; 177: 4521-4529.
21. Crespo J, Sun H, Welling TH, Tian Z, Zou W., T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013; 25: 214-221.
22. Pasare C, Medzhitov R., Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003; 299: 1033-1036.
23. Pardoll D., Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015; 42: 523-538.
24. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
25. Villadolid J, Amin A., Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015; 4: 560-575.
26. Aranda F, Vacchelli E, Obrist F, et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology. 2014; 3: e29179.
27. Kienle GS, Kiene H., Review article: influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010; 9: 142-157.
28. Kienle GS, Glockmann A, Schink M, Kiene H., Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009; 28: 79.
29. Beuth J, Ko HL, Tunggal L, et al. Immunoactive action of mistletoe lectin-1 in relation to dose [in German]. Arzneimittelforschung. 1994; 44: 1255-1258.
30. Orange M, Lace A, Fonseca MP, Laue BH, Geider S, Kienle GS., Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: two case reports. Global Adv Health Med. 2012; 1: 18-25.
31. Orange M, Fonseca M, Lace A, Laue HB, Geider S., Durable tumour responses following primary high dose induction with mistletoe extracts: two case reports. Eur J Integr Med. 2010; 2: 63-69.
32. Jacobson JS, Grann VR, Gnatt MA, et al. Cancer outcomes at the Hufeland (complementary/alternative medicine) klinik: a best-case series review. Integr Cancer Ther. 2005; 4: 156-167.
33. Hobohm HU., Healing Heat. Norderstedt, Germany: BoD; 2014.
34. Kovacs E, Link S, Toffol-Schmidt U,. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung. 2006; 56: 467-473.
35. Lee CH, Kim JK, Kim HY, Park SM, Lee SM., Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo. Int Immunopharmacol. 2009; 9: 1555-1561.
36. Park HJ, Hong JH, Kwon HJ, et al. TLR4-mediated activation of mouse macrophages by Korean mistletoe lectin-C (KML-C). Biochemical and biophysical research communications. 2010; 396 (3): 721-725.
37. Stein GM, Stettin A, Schultze J, Berg PA., Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs. 1997;(suppl 1): S57-S59.
38. Penter R, Dorka R, Frühwirth M, et al. Die Fieberwirkung unter hochdosierter Gabe von Viscum-Präparaten bei der Mistelerstbehandlung: Teil I. Merkurstab. 2002; 5: 330-368.
39. Becker KP, Ditter B, Nimsky C, Urbaschek R, Urbaschek B., Endotoxin contents of phytopharmaceuticals: correlation with clinically observed side effects [in German]. Dtsch Med Wochenschr. 1988; 113: 83-87.
40. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420.
41. Hoos A, Wolchok JD, Humphrey RW, Hodi FS., CCR 20th anniversary commentary: immune-related response criteria-capturing clinical activity in immuno-oncology. Clin Cancer Res. 2015; 21: 4989-4991.
42. Black MS, Opler S, Speer S., Structural representations of tumor-host relationships in gastric carcinoma. Surg Gynec Obstet. 1956; 102: 599-603.
43. Dunn GP, Old LJ, Schreiber RD., The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137-148.
44. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106: dju124.
45. van Der Veen AH, ten Hagen TL, de Wilt JH, van Ijken MG, Eggermont AM., An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application. Anticancer Res. 2000; 20: 3467-3474.
46. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU., Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986; 4: 234-243.
47. Parkinson DR., Interleukin-2 in cancer therapy. Semin Oncol. 1988; 15 (6, suppl 6): 10-26.
48. Dickson JA., Hyperthermia in the treatment of cancer. Lancet. 1979; 303: 202-205.
49. Trieb K, Sztankay A, Amberger A, Lechner H, Grubeck-Loebenstein B., Hyperthermia inhibits proliferation and stimulates the expression of differentiation markers in cultured thyroid carcinoma cells. Cancer Lett. 1994; 87: 65-71.
50. Dickson JA, Calderwood SK., Temperature range and selective sensitivity of tumors to hyperthermia: a critical review. Ann N Y Acad Sci. 1980; 335: 180-205.
51. Chu KF, Dupuy DE., Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014; 14: 199-208.
52. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer. 1967; 20: 1351-1381.
53. Giovanella BC, Stehlin JS Jr, Morgan AC., Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res. 1976; 36 (11, pt 1): 3944-3950.
54. Basu S, Srivastava PK., Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol. 2003; 15: 1053-1061.
55. Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med. 2005; 201: 1435-1446.
56. Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr., Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 2005; 65: 10059-10067.
57. Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004; 199: 775-784.
58. Fritz JH, Girardin SE, Fitting C, et al. Synergistic stimulation of human monocytes and dendritic cells by toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol. 2005; 35: 2459-2470.
59. Netea MG, Ferwerda G, de Jong DJ, et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol. 2005; 174: 6518-6523.
60. Yang S, Takahashi N, Yamashita T, et al. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. J Immunol. 2005; 175: 1956-1964.